NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Heqet Therapeutics

Heqet Therapeutics

Private
TorinoHealthcare & Life Scienceshttps://www.heqettherapeutics.com/

Last Round

Series A

Mar 23, 2022

Total Funding Raised

$8.7M

Company Overview

Heqet Therapeutics is a biotechnology company that develops non-coding RNA-based therapies for cardiovascular diseases, with a particular emphasis on acute myocardial infarction.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

cardiac regenerationnon-coding RNA therapyncRNA therapymicroRNA therapymiRNA therapyLNP deliverylipid nanoparticlesheart attack therapyheart repairRNA therapeuticsregenerative medicinemyocardial infarctionpreclinical biotechcardiomyocyte proliferationheart failure therapydrug discoverymyocardial delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Heqet Therapeutics Comparables

Compare Heqet Therapeutics with similar companies based on industry and business-model similarity.

Heqet Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Prolifagen
85%
Jaan Biotherapeutics
84%
Summa Biotech BV
84%

Heqet Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 23, 2022

Heqet Therapeutics Investors

Notable investors and investment history

Heqet Therapeutics investors
InvestorRounds
Deutsche BalatonSeries A
Claris VenturesSeries A
2invest AGSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2026

    Monthly visitors grew 122% MoM, reaching 1.1K.

  • Nov 18, 2024

    Monthly visitors increased 45% MoM.

Heqet Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Heqet Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Heqet Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersTorino
Employee Range2
Year Founded2021
Last FundingMar 23, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.